Pharvaris
PHVS
31.68
+0.56
+1.80%
Pharvaris
US · PHVS
#2729 by market cap
Listed 2021
31.68
+0.56
+1.80%
Live - 5344 symbols - heartbeat 399s ago
· 2026-10-07 19:54
After-hours
31.68
0.00%
- Market cap
- 2.22B
- P/E (TTM)i
- -10.88
- P/Bi
- 6.60
- EPSi
- -3.33
- Div yieldi
- 0.00%
- 52W posi
- 49%
Reader sentiment
Are you bullish or bearish on PHVS?
Anonymous reader poll. Unscientific, not investment advice.
About Pharvaris
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
- Founded
- 2015
- CEO
- Mr. Berndt Modig
- Employees
- 129
- Headquarters
- Leiden, Zuid-Holland, Netherlands (the)
- Fiscal year end
- 12-31
- Website
- pharvaris.com
Company profile
- Exchange
- US
- Symbol
- PHVS
- Market-cap rank
- #2729
- Listing date
- 2021-02-05
- Market cap
- 2.22B
- Float cap
- 1.40B
- Shares out
- 70.20M
- Float shares
- 44.13M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.